Document is current
Any future updates will be listed below
-
Authors
Lemarchant, Sighild
Engelhardt, Britta
Cicchetti, Francesca
Bix, Gregory J.
Janus, Annette
Godfrin, Yann
Blasco, Hélène
Campbell, Matthew
de Rus Jacquet, Aurélie
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 3 July 2025
First Online: 10 July 2025
Declarations
:
: SL and AJ are employed by Axoltis Pharma and are respectively chief scientific officer and chief medical officer of the company. YG is chief executive officer and a shareholder of Axoltis Pharma. BE, GB, FC and MC are members of the scientific advisory board (SAB) of Axoltis Pharma. BE and MC are members of the SAB of Neuvasq Biotechnologies. As employees, chief executive officer, or SAB members of companies working on drug candidates for barrier repair in neurological disorders, we have deliberately chosen to stay neutral on the third part of this review by just reporting factual elements without interpretation and comparison of the mechanisms of action of the drug candidates being developed, to avoid any conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
